## 2 Results and Discussion
### Results
#### 2.1.4 Bioarth Scale Assessment
\begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline \hline  & & & & & \multicolumn{3}{c}{**95\% Confidence Interval**} & & \multicolumn{1}{c}{\(p\)**-Value**} \\
**Variable** & **Time** & **Group** & \(N\) & **Mean Std. Deviation** & **for Mean** & **Minimum** & **Maximum** & **between** \\  & & & & & & **Lower Bound** & **Upper Bound** & & & **Groups** \\ \hline \multirow{8}{*}{OA degree} & aMSCs & 34 & 15.47 & 6.02 & 13.37 & 17.57 & 3.00 & 21.00 & \multirow{8}{*}{0.259} \\  & baseline & PRGF & 36 & 17.36 & 3.80 & 16.07 & 18.65 & 10.00 & 21.00 & \\  & Total & 70 & 16.44 & 5.06 & 15.24 & 17.65 & 3.00 & 21.00 & \\ \cline{2-10}  & & aMSCs & 34 & 15.62 & 6.11 & 13.49 & 17.75 & 3.00 & 21.00 & \\  & 1 month & PRGF & 36 & 17.36 & 3.80 & 16.07 & 18.65 & 10.00 & 21.00 & 0.339 \\  & & Total & 70 & 16.51 & 5.10 & 15.30 & 17.73 & 3.00 & 21.00 & \\ \cline{2-10}  & & aMSCs & 34 & 15.74 & 6.16 & 13.59 & 17.88 & 3.00 & 21.00 & \\  & 3 months & PRGF & 36 & 17.39 & 3.81 & 16.10 & 18.68 & 10.00 & 21.00 & 0.402 \\  & & Total & 70 & 16.59 & 5.12 & 15.36 & 17.81 & 3.00 & 21.00 & \\ \cline{2-10}  & & aMSCs & 32 & 15.75 & 6.44 & 13.43 & 18.07 & 3.00 & 21.00 & \\  & 6 months & PRGF & 34 & 17.18 & 3.82 & 15.84 & 18.51 & 10.00 & 21.00 & 0.714 \\  & & Total & 66 & 16.48 & 5.26 & 15.19 & 17.78 & 3.00 & 21.00 & \\ \hline \multirow{8}{*}{\begin{tabular}{c} baseline \\ \end{tabular} } & aMSCs & 34 & 5.88 & 2.83 & 4.90 & 6.87 & 2.00 & 11.00 & \multirow{8}{*}{0.003} \\  & baseline & PRGF & 36 & 8.22 & 3.39 & 7.08 & 9.37 & 1.00 & 14.00 & 0.003 \\  & Total & 70 & 7.09 & 3.32 & 6.29 & 7.88 & 1.00 & 14.00 & \\ \cline{2-10}  & & aMSCs & 34 & 2.85 * & 1.94 & 2.18 & 3.53 & 0.00 & 7.00 & \\  & 1 month & PRGF & 36 & 4.56 * & 2.75 & 3.62 & 5.49 & 0.00 & 10.00 & 0.009 \\  & & Total & 70 & 3.73 & 2.52 & 3.13 & 4.33 & 0.00 & 10.00 & \\ \hline \multirow{8}{*}{\
\begin{tabular}{c} Limitation \\ \end{tabular} } & aMSCs & 34 & 2.26 * & 1.75 & 1.66 & 2.87 & 0.00 & 6.00 & \multirow{8}{*}{0.181} \\  & 3 months & PRGF & 36 & 3.33 * & 2.95 & 2.34 & 4.33 & 0.00 & 12.00 & 0.181 \\  & & Total & 70 & 2.81 & 2.48 & 2.22 & 3.41 & 0.00 & 12.00 & \\ \cline{2-10}  & & aMSCs & 30 & 1.80 * & 1.54 & 1.22 & 2.38 & 0.00 & 5.00 & \\  & 6 months & PRGF & 34 & 3.71 * & 2.76 & 2.74 & 4.67 & 0.00 & 9.00 & 0.004 \\  & & Total & 64 & 2.81 & 2.45 & 2.20 & 3.42 & 0.00 & 9.00 & \\ \hline \multirow{8}{*}{
\begin{tabular}{c} baseline \\ \end{tabular} } & aMSCs & 34 & 4.18 & 0.63 & 3.96 & 4.39 & 3.00 & 5.00 & \multirow{8}{*}{0.131} \\  & baseline & PRGF & 36 & 3.92 & 0.84 & 3.63 & 4.20 & 2.00 & 6.00 & 0.131 \\  & & Total & 70 & 4.04 & 0.75 & 3.86 & 4.22 & 2.00 & 6.00 & \\ \cline{2-10}  & & aMSCs & 34 & 2.4 * & 1.23 & 1.98 & 2.84 & 0.00 & 4.00 & \\  & 1 month & PRGF & 36 & 2.97 * & 0.88 & 2.68 & 3.27 & 1.00 & 4.00 & 0.057 \\  & & Total & 70 & 2.70 & 1.09 & 2.44 & 2.96 & 0.00 & 4.00 & \\ \cline{2-10}  & & aMSCs & 34 & 1.38 * & 1.52 & 0.85 & 1.91 & 0.00 & 4.00 & \\ \cline{2-10}  & 3 months & PRGF & 36 & 2.75 * & 1.02 & 2.40 & 3.10 & 1.00 & 4.00 & 0.000 \\  & & Total & 70 & 2.09 & 1.45 & 1.74 & 2.43 & 0.00 & 4.00 & \\ \cline{2-10}  & & aMSCs & 32 & 1.09 * & 1.40 & 0.59 & 1.60 & 0.00 & 4.00 & \\ \cline{2-10}  & 6 months & PRGF & 34 & 2.82 * & 1.00 & 2.47 & 3.17 & 1.00 & 4.00 & 0.000 \\  & & Total & 66 & 1.98 & 1.48 & 1.62 & 2.35 & 0.00 & 4.00 & \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Mean \(\pm\) SD of the functional limitation, joint mobility and range of motion, at baseline, one, three and six months after treatment. Kruskal-Wallis results between groups. * Differences with baseline. Both groups showed significant improvement in functional limitation at all the times evaluated.